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Abstract
Background: Surgical site infection (SSI) is a common complication following abdominal surgery. It is associated
with considerable morbidity and mortality, and its management results in significant cost to health services within
both primary and secondary care. Some surgeons believe that the use of a wound-edge protection device may
reduce the incidence of SSI. Whilst there is some encouraging evidence showing that such devices may lead to a
reduction in SSI, there are no controlled trials of sufficient size or quality to support their routine use.
Methods/Design: 750 patients will be recruited from around 20 surgical units within the United Kingdom. Patients
undergoing laparotomy through any major abdominal incision for any indication, elective or emergency, are eligible.
Patients under the age of 18, those undergoing a laparoscopic assisted procedure or who have undergone laparotomy
within the previous 3 months, and those who are unable to give informed consent will be excluded. Patients will be
randomised (1:1 ratio) to the use of a wound-edge protection device or no wound-edge protection device during surgery.
Follow up will consist of blinded clinical wound reviews at 5-7 days and 30-33 days postoperatively with a self-
completed questionnaire covering the intervening period. Quality of life questionnaires will be completed prior to
surgery and at the subsequent wound review points and information on resource usage will also be captured.
The primary outcome measure is SSI within 30 days of surgery. Secondary outcomes include the impact of the
degree of wound contamination, patient comorbidity, and operative characteristics on the efficacy of a wound-
edge protection device in reducing SSI and whether the use of a wound-edge protection device has an effect on
health-related quality of life or length of hospital stay and is cost-effective.
Discussion: Rossini is the first multicentre observer-blinded randomised controlled trial of sufficient size and quality
to establish whether the use of a wound-edge protection device in adult patients undergoing abdominal surgery
leads to a lower rate of SSI. The results of this study will be used to inform current surgical practice and may
potentially benefit patients undergoing surgery in the future.
Trial registration number: Current Controlled Trials ISRCTN: ISRCTN40402832
Background
Surgical site infection (SSI) is one of the most common
postoperative complications and occurs in at least five
percent of all patients undergoing surgery [1]. The rate
of SSI is significantly higher after open abdominal
surgery which can carry an SSI risk of up to 40%
depending on the level of contamination [2].
SSI is associated with considerable morbidity and it
has been reported that over one-third of postoperative
deaths are related, at least in part, to SSI [3]. It must be
appreciated, however, that the diagnosis covers a wide
spectrum of clinical conditions ranging from a relatively
trivial wound discharge with no other complications to
a life-threatening condition. Other clinical outcomes of
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ble, such as those that are hypertrophic or keloid, per-
sistent pain and itching and a significant impact on
emotional wellbeing [4].
SSI can double the length of time a patient stays in
hospital and thereby increase the costs of health care.
Additional costs attributable to SSI of between £814 and
£6626 per case have been reported depending on the
type of surgery and the severity of the infection [5,6].
The main additional costs are related to re-operation,
extra nursing care and interventions, and drug treatment
costs. The indirect costs, due to loss of productivity,
patient dissatisfaction and litigation, and reduced quality
of life, have been studied less extensively.
Recent national guidelines concerning the prevention
and treatment of SSI have been issued by the National
Institute for Health and Clinical excellence (NICE) [7].
These recommendations are based on systematic reviews
of best available evidence, or when minimal evidence is
available the guideline development group’so p i n i o no f
what constitutes good practice. Intra-operative guidance
includes the role of hand decontamination, sterile gowns
and drapes and antiseptic skin preparation. Wound-edge
protection devices are not discussed in these guidelines,
presumably due to the paucity of published research into
their use and efficacy in the prevention of infection
It is notable that some adhesive plastic ‘incise’ drapes,
favoured by some surgeons, are not recommended in the
guidelines. A recent Cochrane review and meta-analysis
f o u n dt h a tt h e ym a yi n c r e a s et h ec h a n c eo fa nS S I[ 8 ] .
Iodine-impregnated incise drapes fare better (in terms of no
added risk) but still do not offer a significant improvement
in wound infection rate compared with no drape at all.
Wound-edge protection devices
Some surgeons advocate the use of a wound edge pro-
tector or ‘wound guard’ to reduce SSI. There are several
different devices on the market but they all share the
same basic design - a semi-rigid plastic ring placed into
the abdomen via the laparotomy wound to which an
impervious drape is circumferentially attached. This
p l a s t i cd r a p ec o m e su pa n do u to ft h ew o u n do n t ot h e
skin surface, thus protecting the cut wound edges. The
proposed mechanism of action of the device is two-fold.
Firstly, they create a physical barrier between the
abdominal wound edges and viscera, visceral contents,
contaminated instruments and gloves - thus reducing
accumulation of endogenous and exogenous bacteria on
the wound edges. They also potentially reduce tissue
necrosis from long procedure exposure as well as per-
forming a degree of mechanical retraction which in turn
may reduce the need for handheld mechanical retraction
and the tissue damage associated therein. Smaller ver-
sions of wound-edge protection devices are also
currently often used in laparoscopic-assisted resections
of colorectal malignancies to prevent seeding of tumour
cells into wound edges.
As mentioned above, these devices were not considered
at all in the NICE guidelines and there has been minimal
formal research evaluating their value. Two recent
descriptive studies of their use failed to provide strong
conclusions [9,10]. More encouragingly, two separate
small randomised controlled trials (RCTs) comparing use
o ft h ed e v i c ea g a i n s ts t a n dard treatment did show
encouraging results [11,12], with a variable rate of reduc-
tion of up to 84% depending on degree of wound con-
tamination. However, the trials were both single-centre
and not without some shortcomings in design, in particu-
lar relating to randomisation strategy, blinding of
researchers and follow-up protocols. All other research
into the devices is over 25 years old and assesses older-
generation devices in a different era to that of today in
terms of the background advances in infection prophy-
laxis. Table 1 summarises the published data on the
usage of wound-edge protectors [9-16]. There is no sys-
tematic review or meta-analysis of the use of a wound-
edge protector. This probably accounts for the limited
uptake of the device amongst the general surgeons of
today. The highest level of evidence regarding the devices
probably comes from a review of the Sookhai RCT [11]
in the Evidence-Based Medicine journal soon after its
publication [17]; the conclusion of this review was that
whilst there was evidence that the device reduced SSI
(particularly in operations with a higher level of contami-
nation), wider application of the device should await the
result of a more rigorously designed multicentre study.
Issues relating to a potential randomised controlled trial
of wound-edge protectors
1 No multicentre trial has been done
2 No current data explores efficacy in prevention of
early versus late SSI
3 No current data explores pathogen bias in SSI pre-
vented (or not prevented) by the device
We propose a prospective multicentre randomised
controlled trial that will address all of these issues.
Primary Hypothesis
Use of a wound-edge protection device in adults under-
going laparotomy will result in a reduced rate of surgical
site infection (SSI).
Methods/Design
Study Design
A prospective, multicentre, observer blinded, rando-
mised controlled trial with stratification according to
baseline infection risk
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The study will take place in general surgical units within
the NHS. Surgical units in the West Midlands are being
approached as are units in London, Southampton, Ply-
mouth and Trent. Twelve sites are being identified to
collaborate in the trial initially.
Ethical Approval
Full ethical approval has been gained from the North
Staffordshire Research Ethics Committee (ref: 09/
H1204/91).
Inclusion Criteria
All adults undergoing laparotomy via midline, transverse
or Kocher’s incision (for any surgical indication), includ-
ing both elective and emergency operations
Exclusion Criteria
￿ Patients less than 18 years of age, or unable to give
informed consent
￿ Laparoscopic-assisted cases
￿ Previous laparotomy within the past 3 months
Primary outcome measure
The primary outcome is Surgical Site Infection (SSI)
within 30 days of surgery.
Positive identification of SSI will be determined with
use of the internationally accredited Centers for disease
Control and Prevention (CDC) definitions.
We hypothesise that the use of wound-edge protection
device in adults undergoing laparotomy will result in a
reduced rate of surgical site infection of 50% based on
evidence from Horiuchi et al, 2007 [12].
The power calculations for a range of baseline infec-
tion rates and this assumed 50% reduction in SSI rate
brought about by use of the device are shown in table 2.
A conservative estimate of infection rate of 12% requires
a total of 710 patients, randomised 1:1 between treatment
and placebo. Thus we intend to recruit 750 patients in
total in order to provide adequate power should our
assumptions informing the power calculation prove opti-
mistic, and to accommodate a potential 5% dropout rate.
Secondary Outcomes
Comparisons will be made to assess the impact of treat-
ment relating to the following outcomes:
1) The degree of wound contamination (e.g. colorec-
tal resections/vascular surgery)
2) Presence of major comorbidity (e.g. diabetes, obe-
sity, smoking)
3) Health-related quality of life (QoL) to be assessed
using the EQ-5D questionnaire
Table 1 Summary of published data on wound edge protection devices
Lead
Author
Year of
Publication
Title Type of Study Comments
Horiuchi
[12]
2007 Randomised, controlled investigation of the anti-infective
properties of the Alexis retractor/protector of incision
sites
RCT; 2 arms - control vs.
wound-edge protector
Looks well-designed
221 patients
Positive results
Single centre
Kercher [9] 2004 Plastic wound protectors do not affect wound infection
rates following laparoscopic-assisted colectomy
Retrospective review Descriptive study only
141 patients
Laparoscopic cases
Nakagoe
[10]
2001 Minilaparotomy wound edge protector (Lap-protector): a
new device
Description of technique Descriptive study only
No comparison group
Sookhai
[11]
1999 Impervious wound-edge protector to reduce
postoperative wound infection: a randomised, controlled
trial
RCT; 2 arms -control vs.
wound-edge protector
Looks well-designed
352 patients
Positive results
Single centre
Nystrom
[13]
1983 A controlled trial of plastic wound ring drape to prevent
contaminations and infection in colorectal surgery
RCT; 2 arms - control vs.
wound-edge protector
140 patients
No benefit found
Old-generation device
Psaila [14] 1977 The role of plastic wound drapes in the prevention of
wound infection following abdominal surgery
RCT; 3 arms - control vs.
adhesive drape vs. wound-
edge protector
154 patients
No benefit from either device
Poor follow-up
Alexander
-Williams
[15]
1972 Abdominal wound infections and plastic wound guards RCT; 2 arms - control vs.
wound-edge protector
167 patients
Poor follow-up to 10 days only
Inconsistent design
Maxwel
[16]
1969 Abdominal wound infections and plastic drape protectors Comparative study No randomisation
Poorly designed study
202 patients
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5) Health care utilisation and the incremental cost-
effectiveness of the use of the wound-edge protec-
tion device compared to standard care
6) Adverse events
Randomisation
The most important factor in determining risk of SSI is
the type of surgery performed via the laparotomy
wound and resulting degree of contamination. The stan-
dard categorisation and corresponding normal infection
rates [18] are shown in table 3.
Randomisation will therefore be stratified according to
degree of contamination using a minimisation procedure
following the methods proposed by Pocock and Simon
(1975) [19] using a programme developed by Dr Mela-
nie Calvert, University of Birmingham.
Please refer to the randomisation notepad (Additional
file 1 Table S1) for details of operation-specific informa-
tion to be collected prior to randomisation.
Data Management
This is being supported by the Primary Care Clinical
Trials Unit at the University of Birmingham. Data will
be stored securely as a hard copy version and on com-
puterised data bases (ACCESS).
Statistical analysis
All analyses will be pre-specified and conducted accord-
ing to the intention-to-treat principle with the use of
SAS software (version 9.1, SAS Institute). P values other
than for the primary end point are nominal.
Analysis of Primary and Secondary Outcomes
The primary outcome will be analysed using generalised
linear models, with logit link, binomial error and with
surgeon as random effects. Odds ratio 95% CI and p
value will be presented. Continuous data will be ana-
lysed with the use of mixed models, which include sur-
g e o n sa sr a n d o me f f e c t s[ 2 0 ] .T h er a t e so fa d v e r s e
events shall be compared between groups by means of
Fisher’s exact test.
Exploratory analysis on the primary outcome
If a statistically significant result is observed for the pri-
mary outcome a parsimonious statistical model describ-
ing the predictive value of variables listed will be
estimated, using a stepwise model building procedure
(Additional file 2 Appendix 1). The linearity in response
of continuous variables will be examined using restricted
cubic splines. Interaction terms will be assessed and
Akaike’s Information Criterion will be used to determine
the best model fit [21].
Cost-effectiveness Analysis
A prospective within trial cost-effectiveness analysis will
be undertaken based on ITT analysis of all patients
enrolled in the study. The incremental cost per quality
adjusted life year (QALY) gained and incremental cost
per life year gained of the alternate treatment options
will be assessed during the trial to inform clinicians and
policy makers of the cost effectiveness of the alternative
therapies.
Data Safety Monitoring
A steering committee developed the protocol and will
provide academic leadership for the overall conduct of
the trial. An independent data and safety monitoring
board will be appointed who will undertake 4 interim
analyses on safety and efficacy. Although the exact
details of the statistical plan will be determined by the
committee, it is anticipated that a truncated modified
O’Brien Flemming alpha spending plan will be used for
efficacy, and a non symmetrical power function will be
Table 2 Infection rates and sample size
Infection rate in untreated group Expected infection rate in treated group Overall sample size Sample size in each arm
18% 9% 448 224
15% 7.5% 554 277
12% 6% 710 355
(80% power and 0.05 significance level)
Table 3 Classification of potential surgical contamination
Type of Surgery Examples Normal Infection Rate (%) [18]
Clean (no viscus opened) Adhesiolysis 1-2
Clean-contaminated (viscus opened, minimal spillage) Right Hemicolectomy,
Open Cholecystectomy
<1 0
Contaminated (open viscus with spillage or inflammatory disease) Colectomy with some spillage
Resection of active Crohns disease
15-20
Dirty (pus or perforation, or incision through an abscess) Diverticular perforation < 40
Pinkney et al. Trials 2011, 12:217
http://www.trialsjournal.com/content/12/1/217
Page 4 of 6used for safety (increasing the likelihood of early stop-
ping for safety).
Trial Management Protocols
Two named principle investigators (PI) will be recruited
at each study site. Together they shall provide blinded
wound reviews for the other PI’s patients by being una-
ware of which arm of the study these patients belong to.
The two wound reviews will occur firstly prior to dis-
charge at day 5 to 7 post-operation and then a formal
outpatient appointment or ward attendance for wound
review will be arranged at or just after 30 days (day 30-
33 post-operation). At this visit patients will also be
asked to complete a retrospective questionnaire regard-
ing their wound and its healing over the intervening
period. This will ensure that full information is gathered
about any wound infections, together with resulting
treatment or hospital admissions, occurring between the
day 5-7 and day 30-33 reviews. Enrolled patients will
also be given contact details for the local primary inves-
tigator should any concerns by raised by the patient.
Wound assessment at both stages will utilise a standar-
dised proforma. These wound assessment tools will be
pre-validated for reproducibility and ease-of-use in a
pilot study to be ran prior to full trial launch.
QOL data will be assessed using the EQ-5D pre-
operatively, at 5-7 days, at the 30-33 day follow-up visit.
We also envisage the involvement of clinical nurse spe-
cialists at most sites. Their clinic appointments are gener-
ally more accessible and it may be feasible to utilise these
for the second formal (outpatient) wound review. Clinical
nurse specialists are generally experienced in assessing
post-operative wounds themselves and they may also
therefore provide a second-line cohort of blinded wound
reviewers if the relevant PI is not available.
Study Process
Data will be recorded on a number of case report forms
which are detailed in Additional file 3 Appendix 2. Fig-
ure 1 gives an overview of the study process.
1. Informed consent for participation in the study is
obtained preoperatively, ideally at the same setting
where (normal) consent for the intended surgical
procedure is obtained > 24 hrs prior to surgery
(except in an emergency setting). Patients will ideally
have been previously given a patient information
sheet at the time of listing for their operation.
2. After induction of anaesthesia at the time of sur-
gery the patient is allocated to either the wound-
edge protector group or the control (no protector)
group by the surgeon, using a secure 24 hour inter-
net-based randomisation service - provided by the
UKCRC Accredited Primary Care Clinical Trials
Unit, University of Birmingham.
3. Normal local policy for systemic antibiotic pro-
phylaxis is followed.
4. Standard routine skin preparation is undertaken
according to local policy.
5. Antiseptic-soaked towels on wound edges may
also be used in either group.
Figure 1 Flowchart Illustrating Study Process.
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removal of the wound guard (if applicable) as late as
possible prior to wound closure.
Additional material
Additional file 1: Table S1. Randomisation Notepad.
Additional file 2: Appendix 1. Exploratory analysis on the primary
outcome.
Additional file 3: Appendix 2. Case report form definitions.
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